Alcon Inc., headquartered in Geneva, Switzerland, is a global leader in eye care. The company became an independent, publicly traded entity in April 2019, following being spun out of Novartis. In the transition from private to public, management and the board had to balance Swiss public company pay practices, continued executive retention and overall reward fairness, all within a newly public company context.
At the time of listing, no additional value was delivered to executives through on-listing incentives, but transitional arrangements were put in place to ensure that executives weren’t disadvantaged in respect of legacy incentive awards. These took the form of Keep Whole Awards, to replace the payment of a dividend in kind, and Refill Awards, to replace the forfeited portion of the original Novartis Performance Share Units (PSU) awards.
Following listing, with the transition from being a subsidiary of Novartis to being an independent public company, the executive team received a remuneration package reflective of their increased strategic and operational responsibilities. While a subsidiary of Novartis, the total target LTIP opportunity for executive committee members ranged from 160% to 270% of base salary.
Following the IPO, the LTIP opportunity was materially increased and, in 2019, LTI awards were granted to the CEO with a target opportunity of 280% of base salary. The awards consisted of Performance Share Units (PSU), which convert to shares at vesting, contingent on the achievement of performance measures. As noted by the company, this increase, effective from the spin-off date, reflected the new responsibilities as executives of an independent public company.